Gainers

• Akanda (NASDAQ:AKAN) shares increased by 36.3% to $16.5 during Tuesday's regular session. The market value of their outstanding shares is at $6.4 million.
• Pomdoctor (NASDAQ:POM) shares moved upwards by 32.37% to $0.4. The company's market cap stands at $36.0 million.
• Atlantic International (NASDAQ:ATLN) stock increased by 23.08% to $1.97. The market value of their outstanding shares is at $126.9 million.
• Omnicell (NASDAQ:OMCL) shares moved upwards by 20.05% to $45.17. The company's market cap stands at $1.7 billion. As per the press release, Q1 earnings came out today.
• bioAffinity Technologies (NASDAQ:BIAF) shares moved upwards by 19.02% to $2.63. The market value of their outstanding shares is at $9.9 million.
• InflaRx (NASDAQ:IFRX) stock moved upwards by 18.63% to $1.91. The company's market cap stands at $116.3 million.

Losers

• Soligenix (NASDAQ:SNGX) stock decreased by 70.0% to $0.42 during Tuesday's regular session. The market value of their outstanding shares is at $14.2 million.
• Erasca (NASDAQ:ERAS) stock declined by 46.22% to $10.3. The company's market cap stands at $5.9 billion.
• Picard Medical (AMEX:PMI) stock declined by 27.52% to $0.5. The market value of their outstanding shares is at $52.0 million.
• Aspire Biopharma Holdings (NASDAQ:ASBP) shares declined by 15.7% to $0.21. The market value of their outstanding shares is at $1.2 million.
• Werewolf Therapeutics (NASDAQ:HOWL) shares decreased by 14.02% to $0.71. The company's market cap stands at $40.3 million.
• Artiva Biotherapeutics (NASDAQ:ARTV) shares declined by 13.4% to $9.31. The company's market cap stands at $263.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.